Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4380 - Biomarker analysis using circulating tumor DNA in patients treated with sorafenib for advanced hepatocellular carcinoma


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Hepatobiliary Cancers


Sook Ryun Park


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


S.R. Park1, C.R. Oh2, S. Kong3, M.K. Kim4, K. Yoon5, E. Cho6, J. Jang6, J. Lee6, B. Ryoo7

Author affiliations

  • 1 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 2 Department Of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 3 Department Of Laboratory Medicine, Hospital, National Cancer Center, 10408 - Goyang/KR
  • 4 Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, 10408 - Goyang/KR
  • 5 College Of Veterinary Medicine, Konkuk University, 05029 - Seoul/KR
  • 6 Genome Research Center, Green Cross Genome, Yongin/KR
  • 7 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR


Abstract 4380


We aimed to investigate potential biomarkers in patients treated with sorafenib for advanced hepatocellular carcinoma (HCC) using circulating tumour DNA (ctDNA).


155 patients who had started sorafenib between March 2014 and November 2016 were identified from a prospective biomarker cohort of Asan Medical Center, Korea. We quantified the concentration of ctDNA extracted from blood samples of each patient collected before sorafenib treatment and measured the copy numbers of vascular endothelial growth factor-A (VEGFA) in ctDNA. We also applied low depth whole genome sequencing from ctDNA to find copy number aberrations in HCC and employed Q-score, defined as a standard deviation regarding Z-scores of sequenced reads on each chromosome.


Among 155 patients, 124 were finally included in the analysis. 82 patients achieved partial response, stable disease or non-CR/non-PD with sorafenib treatment (non-PD group) whereas 42 exhibited progressive disease (PD group). The PD group had significantly higher levels of ctDNA concentrations than the non-PD group (153.3 vs. 109.3 ng/mL; p = 0.038). Q-score of PD group was also higher than that of non-PD group but there was a borderline significant difference between two groups (6.10 vs. 3.80; p = 0.058). VEGFA copy number, which was available for only 41 patients, did not differ between PD (n = 16) and non-PD (n = 25) groups (2.56 vs. 2.48; p = 0.467). Divided into two groups based on the median value (119.7 ng/mL) of ctDNA concentrations, patients with high ctDNA had significantly shorter time to progression (TTP) (median, 2.3 vs. 4.1 months; p = 0.025) and overall survival (OS) (median, 4.5 vs. 14.8 months; p 


Our results showed that ctDNA level and copy number aberrations represented by Q-score could be potential prognostic biomarkers in HCC patients treated with sorafenib.

Clinical trial identification

Legal entity responsible for the study

Department of Oncology, Asan Medical Center, Seoul, Republic of Korea




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.